Question

Difficulty: HardPediatric Infectious Diseases

A 15-month-old boy is brought to the clinic for a routine well-child examination. Three months ago, he was hospitalized for 5 days with a persistent high fever, bilateral bulbar conjunctival injection, cracked erythematous lips, and a diffuse maculopapular rash. During that admission, he was successfully treated with a single dose of intravenous immunoglobulin (IVIG, 2 g/kg2 \text{ g/kg}) and high-dose aspirin. An echocardiogram performed at the time was normal. He was discharged on low-dose aspirin, which was discontinued last week following a normal follow-up echocardiogram. His last immunizations were administered at his 6-month well-child visit. His temperature is 37.1°C (98.8°F), heart rate is 105/min, and blood pressure is 85/50 mm Hg. Physical examination today shows a well-appearing, active toddler with no abnormalities. The parents are requesting that he receive all vaccines he is currently eligible for to catch up on his schedule. Which of the following is the most appropriate recommendation regarding this patient's immunizations today?

  1. Administer age-appropriate inactivated vaccines today and defer live-attenuated vaccines for 8 more monthsAnswer
  2. B
    Administer all age-appropriate inactivated and live-attenuated vaccines today
  3. C
    Administer age-appropriate inactivated vaccines and the measles-mumps-rubella (MMR) vaccine today; defer the varicella vaccine
  4. D
    Defer all immunizations today and schedule a return visit in 8 more months for full catch-up vaccination
  5. E
    Administer all age-appropriate vaccines today and schedule an additional dose of live-attenuated vaccines in 8 months

Answer

Administer age-appropriate inactivated vaccines today and defer live-attenuated vaccines for 8 more months.
The patient's history of prolonged fever, conjunctivitis, cracked lips, and rash treated with IVIG establishes a diagnosis of Kawasaki disease. Intravenous immunoglobulin (IVIG) consists of pooled IgG antibodies that provide passive immunity but concurrently interfere with the body's ability to mount an immune response to live-attenuated viral vaccines (e.g., MMR, varicella). Because live vaccines require viral replication within the host to produce adequate immunity, circulating exogenous antibodies can neutralize the vaccine viruses, rendering the immunization ineffective. The necessary deferral period depends on the dose of IVIG administered; the high dose used for Kawasaki disease (2 g/kg2 \text{ g/kg}) requires a strict 11-month deferral. Since the patient received IVIG 3 months ago, live-attenuated vaccines must be deferred for an additional 8 months. Conversely, inactivated vaccines (e.g., DTaP, Hib, PCV, HepB, IPV) do not require replication and their immunogenicity is unaffected by IVIG. They should be administered today to keep the child properly protected and on schedule.

Step-by-Step Solution

1
Diagnose the patient's past illness based on the clinical history provided.
The patient had Kawasaki disease (fever, conjunctivitis, mucositis, rash) treated with high-dose IVIG (2 g/kg2 \text{ g/kg}).
Identifying the disease and its specific treatment is required to anticipate any interference with routine preventive care.
2
Determine the interaction between the patient's past treatment (IVIG) and his required 15-month immunizations.
IVIG contains pooled IgG antibodies that neutralize live-attenuated vaccines (like MMR and varicella) but do not affect the immune response to inactivated vaccines.
Understanding which vaccine types are affected dictates which vaccines can be safely and effectively given today.
3
Calculate the required deferral time for the affected vaccines.
High-dose IVIG (2 g/kg2 \text{ g/kg}) requires an 11-month deferral of live vaccines. Because 3 months have passed since the treatment, the live vaccines must be deferred for an additional 8 months.
Passive immunity degrades over time; an 11-month interval ensures exogenous antibodies fall below the threshold that interferes with vaccine virus replication.

Key Concept

Live-attenuated vaccine deferral following intravenous immunoglobulin (IVIG) administration
Rate this question